Skip to main content
Year archive

H. Lundbeck A — 2023 filings

All 28 regulatory filings released by H. Lundbeck A (HLUN) in 2023, sourced directly from the official regulator.

28 Filings
2023 Period
2023 filings (28)
Filing Released Lang
Director's Dealing 2023
Director's Dealing
2023-12-20 English
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Director's Dealing
2023-12-20 Danish
Director's Dealing 2023
Director's Dealing
2023-12-04 English
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Director's Dealing
2023-12-04 English
Regulatory Filings 2023
Regulatory Filings
2023-09-07 English
Lundbeck and Otsuka announce topline results from two phase III trials of brexpiprazole as combination therapy with sertraline for the treatment of Post-Traumatic Stress Disorder in adults
Regulatory Filings
2023-09-07 English
Earnings Release 2023
Earnings Release H1 2023
2023-08-16 English
Lundbeck’s revenue increased by 13% (+10% CER) to DKK 10 billion in the first six months of 2023
Interim / Quarterly Report H1 2023
2023-08-16 English
Board/Management Information 2023
Board/Management Information
2023-06-26 English
Director's Dealing 2023
Director's Dealing
2023-05-15 English
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Director's Dealing
2023-05-15 Danish
Regulatory Filings 2023
Regulatory Filings
2023-05-11 English
Lundbeck and Otsuka announce U.S. Food and Drug Administration (FDA) approval of sNDA for Rexulti® (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer’s Disease
Regulatory Filings
2023-05-11 English
Regulatory Filings 2023
Regulatory Filings
2023-04-19 English
Lundbeck announces positive phase II Proof of Concept results with Lu AG09222 in migraine prevention
Regulatory Filings
2023-04-19 English
Director's Dealing 2023
Director's Dealing
2023-02-14 English
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Director's Dealing
2023-02-14 Danish
Director's Dealing 2023
Director's Dealing
2023-02-10 English
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Director's Dealing
2023-02-10 Danish
Director's Dealing 2023
Director's Dealing
2023-02-08 English
Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties
Director's Dealing
2023-02-08 English
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2023-02-08 English
Report Publication Announcement 2023
Report Publication Announcement
2023-02-08 English
Lundbeck Annual Report 2022
Annual Report FY 2022
2023-02-08 English
Earnings Release 2022
Earnings Release FY 2022
2023-02-07 English
Lundbeck announces financial guidance for 2023 and mid-term financial targets that build on very strong 2022 performance
Earnings Release FY 2022
2023-02-07 English
Regulatory Filings 2023
Regulatory Filings
2023-01-07 English
Lundbeck announces FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer’s dementia
Regulatory Filings
2023-01-07 English